This report represents Multiple Myeloma Research Foundation, Inc.’s responses to Charting Impact, a joint project of BBB Wise Giving Alliance, GuideStar USA Inc, and Independent Sector. Charting Impact uses five simple yet powerful questions to encourage strategic thinking and help organizations share concise information about their plans and progress toward impact.

**Multiple Myeloma Research Foundation, Inc.**
383 Main Avenue 5th Floor, Norwalk, CT 06851
203-652-0231
http://www.themmrf.org

**Mission:**
The Multiple Myeloma Research Foundation, Inc. mission is to: relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. To achieve this purpose, four goals are pursued: Funding research in the field of multiple myeloma, building collaborations among researchers and industry, providing disease and treatment related information to patients and family members while advocating for optimal patient care, and raising awareness of multiple myeloma.
The content of this Charting Impact Report is the sole product and responsibility of Multiple Myeloma Research Foundation, Inc. This report does not in any way represent an endorsement from Independent Sector, BBB Wise Giving Alliance, or GuideStar, nor does it represent fulfillment of the BBB Wise Giving Alliance’s Standards for Charity Accountability. For more information on Charting Impact, visit www.guidestar.org/chartingimpact
1. What are we aiming to accomplish?

The MMRF is singularly focused on the development of new drugs that extend lives and lead to a cure. We pursue this goal by investing in a balanced and targeted research portfolio: Data Bank $5.3M in 2016 — An unprecedented collection of high-quality patient molecular and clinical data. The Learning Network: $5.5M in 2016 — Collaboration that focuses upon access to new targets and drugs to advance trials faster than any organization. The Clinic: $6.3M in 2016 — A network of best-in-class partners launching clinical trials 60% faster than average.

2. What are our strategies for making this happen?

Through the Data Bank, which includes the CoMMpass study: The CoMMpass℠ Study: The MMRF CoMMpass study aims to analyze tissue samples from approximately 1,000 multiple myeloma patients profiled sequentially over 5 years time to define multiple myeloma’s sub-types and to assess which drugs work best for different sub-types. Importantly, all CoMMpass data will be placed in the public domain. Findings will allow us to precisely match patients, based on their sub-type, with treatments that offer the best chance of long-lasting remissions with fewer effects and cures. Through the Learning Network which includes the Researcher and Community Gateways: Researcher and Community Gateways: The MMRF Researcher Gateway will consolidate CoMMpass data with disparate datasets from around the globe and provide basic analytic tools to make data accessible to a diverse group of users—scientists, pharmaceutical companies, health care organizations, physicians, and even patients—without requiring strong IT skills. As a complement to the Researcher Gateway, the MMRF Community Gateway will engage patients in the research process. The Community Gateway will create a dynamic, online community of myeloma patients and will allow patients to better understand their disease and treatment options, to share their data and experiences, and to take action by sharing their data with research studies or by joining clinical trials. Through the Clinic which include the MMRC Consortium: The MMRC Consortium main objective is to continue to facilitate to open clinical trials 60% faster than average which will help to extend lives and lead to a cure for Multiple Myeloma.

3. What are our organization's capabilities for doing this?

The MMRF invests approximately $20M to $24M each year to support the advancement of its research portfolio and advance patient/donor education and awareness. Funding is supported primarily through the support of individual donors. In addition, the MMRF receives research funding through foundation grants, government grants, and pharmaceutical grants. The MMRF is governed by a strong Board of Directors and led by an Executive Committee that provides strategic oversight and operational management. With a breadth of experience spanning pharmaceutical companies, contract research organizations, marketing and communications firms and academia, our leadership has expertise in all aspects of drug discovery and drug development. Partnerships with external organizations have also proven critical to the Foundation's success to date and ongoing and future research initiatives. Our partners include academic institutes, community cancer centers, pharmaceutical and biotech companies, other non-profit organizations, and government entities.

4. How will we know if we're making progress?

The MMRF is a milestone-driven organization. We evaluate the success of each program in our research portfolio from the following measures: The Clinic: □ The number of trials opened each year □ The number of drugs and/or drug classes studied each year □ The number of drug that advance to the next phase of clinical testing The Learning Network: □ The number and/or dollar amount invested in research grants, data gateways Immune Therapy Programs □ Progress reports from grant recipients detailing research milestones □ Publications □ New therapeutic approaches The Data Bank □ The number of patients enrolled in CoMMpass □ □ Meeting pre-established timelines Patient Education/Support Services □ The number of participants at Clinical Insights educational programs □ The number of participants on MMRF web-casts □ The
5. What have and haven't we accomplished so far?

In all we do, we measure our progress by strides toward our ultimate goals: an increase in life expectancy for multiple myeloma patients and a cure for the disease. As mentioned, to date we have accomplished the following:

- Raised more than $300 million to fund numerous research grants at 131 institutions worldwide.
- Played a major role in the FDA approval of ten new treatments in less than 12 years that have doubled patient survival.
- Built the first GLP-quality, myeloma-specific biobank that integrates patient tissue samples with corresponding laboratory and clinical data.
- Sequenced the multiple myeloma genome.
- Launched the MMRF CoMMpass study to understand which kinds of treatments or combination of treatments could work best for specific patients.